Soligenix Inc. Reports Q2 2025 Results with Significant Progress in Rare Disease Treatments
TL;DR
Soligenix's advancements in rare disease treatments, including Phase 2a results for SGX302 in psoriasis and Phase 3 trial of HyBryte(TM) for CTCL, offer investors potential growth opportunities.
Soligenix reported a Q2 2025 net loss of $2.7 million, with R&D expenses rising to $1.7 million due to increased trial and manufacturing costs, while maintaining $5.1 million in cash.
Soligenix's development of treatments for rare diseases like CTCL and Behçet’s Disease represents a significant step forward in improving patient care and quality of life.
Soligenix transfers synthetic hypericin manufacturing to the U.S., marking a strategic move in its partnership with Sterling Pharma Solutions for rare disease treatments.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare disease treatments, has reported its second-quarter results for 2025, showcasing significant progress in its late-stage pipeline. The company is on track to release top-line Phase 2a results for SGX302, a treatment for mild-to-moderate psoriasis, by the end of the year. Additionally, updates from an investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL) are expected, alongside active enrollment in a confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL, with results anticipated in 2026.
The company has also completed a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease, successfully meeting its primary objective of demonstrating biological efficacy. In a strategic move, Soligenix has transferred the manufacturing of synthetic hypericin to the U.S. under its partnership with Sterling Pharma Solutions, marking a significant step in its operational capabilities.
Financially, Soligenix reported a widened net loss of $2.7 million, or ($0.82) per share, compared to $1.6 million in the previous quarter, with research and development expenses increasing to $1.7 million due to higher trial and manufacturing costs. Despite these challenges, the company's cash position stood at $5.1 million as of June 30, 2025, supplemented by an additional $1.4 million raised on July 1, ensuring funding for operations into the first quarter of 2026.
For more detailed information on Soligenix's developments and financials, visit https://ibn.fm/SsFsy.
Soligenix's advancements in rare disease treatments underscore the company's commitment to addressing unmet medical needs. The progress in its pipeline, particularly in psoriasis and CTCL treatments, highlights the potential for significant impact on patient care and the biopharmaceutical industry. With ongoing trials and strategic partnerships, Soligenix is poised to make meaningful contributions to the field of rare disease therapeutics.
Curated from InvestorBrandNetwork (IBN)
